Status:
ACTIVE_NOT_RECRUITING
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Papillomavirus Vaccines
Eligibility:
All Genders
9+ years
Phase:
NA
Brief Summary
The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cer...
Detailed Description
Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). Compared with the age- and...
Eligibility Criteria
Inclusion
- HEALTHCARE PROVIDERS (ONCOLOGISTS, ADVANCED PRACTICE PROVIDERS)
- ≥18y of age
- Care for cancer survivors seen in the targeted clinic who are age 9-17y, ≥1y off-therapy, and reside in the state where clinic is located
- Licensed to order vaccines
- Willing to complete surveys and/or interviews
- CHILDHOOD CANCER SURVIVORS
- 9-17y of age
- ≥1y following completion of cancer therapy
- Reside in the state where clinic is located
- Receive follow-up care (in person or via telehealth) at the participating sites
Exclusion
- N/A
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
5196 Patients enrolled
Trial Details
Trial ID
NCT04469569
Start Date
February 1 2021
End Date
January 31 2026
Last Update
February 3 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Emory University
Atlanta, Georgia, United States, 30322
3
University of Minnesota
Minneapolis, Minnesota, United States, 55455-0341
4
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157-0001